18F-HX4 hypoxia imaging with PET/CT in head and neck cancer: A comparison with 18F-FMISO

Nuclear Medicine Communications

Volumn 33, Issue 10, 2012, Pages 1096-1102

  Chen, Limin ^a   Zhang, Zhengwei ^a   Kolb, Hartmuth C ^b   Walsh, Joseph C ^b   Zhang, James ^b   Guan, Yihui ^a  

^a FUDAN UNIVERSITY   (China)

^b Siemens Molecular Imaging Biomarker Research   (United States)

Author keywords

18F HX4; 18F FMISO; head and neck cancer; hypoxia imaging; PET

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; 3 FLUORO 2 [4 [(2 NITRO 1H IMIDAZOL 1 YL)METHYL] 1H 1,2,3 TRIAZOL 1 YL]PROPAN 1 OL F 18; CARBONATE DEHYDRATASE IX; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; IMIDAZOLE DERIVATIVE; UNCLASSIFIED DRUG; 1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; 3 FLUORO 2 (4 ((2 NITRO 1H IMIDAZOL 1 YL)METHYL) 1H 1,2,3 TRIAZOL 1 YL)PROPAN 1 OL; 3-FLUORO-2-(4-((2-NITRO-1H-IMIDAZOL-1-YL)METHYL)-1H-1,2,3-TRIAZOL-1-YL)PROPAN-1-OL; DIAGNOSTIC AGENT; DRUG DERIVATIVE; MISONIDAZOLE; NITROIMIDAZOLE DERIVATIVE; TRIAZOLE DERIVATIVE; TUMOR MARKER;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CORRELATION ANALYSIS; DRUG SAFETY; DRUG UPTAKE; FEASIBILITY STUDY; FEMALE; HEAD AND NECK CANCER; HUMAN; HYPOXIA; IMMUNOHISTOCHEMISTRY; ISOTOPE LABELING; MALE; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; CELL HYPOXIA; COMPARATIVE STUDY; GENE EXPRESSION REGULATION; GENETICS; HEAD AND NECK TUMOR; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOLOGY; SCINTISCANNING;

ADULT; AGED; AGED, 80 AND OVER; CELL HYPOXIA; FEASIBILITY STUDIES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; MISONIDAZOLE; NITROIMIDAZOLES; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; TRIAZOLES; TUMOR MARKERS, BIOLOGICAL;

EID: 84865709437     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e3283571016     Document Type: Article

References (23)

1. Mottram J. Factor of importance in radiotherapy of tumors. Br J Radiol 1936; 9:606-614.
2. Gray LH, Conger AD, Ebert M, Scott OCA. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 1953; 26:628-654.
3. Nordsmark M, Alsner J, Keller J, Nielsen OS, Jensen OM, Horsman MR, et al. Hypoxia in human soft tissue sarcomas: adverse impact on survival and no association with p53 mutations. Br J Cancer 2001; 84:1070-1075. (Pubitemid 32448504)
4. Brizel DM, Dodge RK, Clough RW, Dewhirst MW. Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. Radiother Oncol 1999; 53:113-117.
5. Nordsmark M, Overgaard M, Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 1996; 41:31-39. (Pubitemid 26396294)
6. Brizel DM, Sibley GS, Prosnitz LR, Scher RL, Dewhirst MW. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1997; 38:285-289. (Pubitemid 27318643)
7. Vaupel P, Schlenger K, Knoop C, Hockel M. Oxygenation of human tumors: evaluation of tissue oxygen distribution in breast cancers by computerized O2 tension measurements. Cancer Res 1991; 51:3316-3322.
8. Vaupel P, Hockel M, Mayer A. Detection and characterization of tumor hypoxia using pO2 histography. Antioxid Redox Signal 2007; 9: 1221-1235. (Pubitemid 47080831)
9. Krause BJ, Beck R, Souvatzoglou M, Piert M. PET and PET/CT studies of tumor tissue oxygenation. Q J Nucl Med Mol Imaging 2006; 50: 28-43.
10. Lee ST, Scott IS. Hypoxia positron emission tomography imaging with 18F-fluoromisonidazole. Semin Nucl Med 2007; 37:451-461. (Pubitemid 47498258)
11. Lehtio K, Oikonen V, Nyman S, Grönroos T, Roivainen A, Eskola O, et al. Quantifying tumour hypoxia with fluorine-18 fluoroerythronitroimidazole ([18]FETNIM) and PET using the tumour to plasma ratio. Eur J Nucl Med Mol Imaging 2003; 30:101-108. (Pubitemid 36692899)
12. Souvatzoglou M, Krause BJ, Machulla HJ, Wester HJ, Piert M. Tumour hypoxia imaging with [18F]FAZA PET in head and neck cancer patients: a pilot study. Eur J Nucl Med Mol Imaging 2007; 34: 1566-1575. (Pubitemid 47476913)
13. Komar G, Seppanen M, Eskola O, Lindholm P, Grönroos TJ, Forsback S, et al. 18F-EF5: a new PET tracer for imaging hypoxia in head and neck cancer. J Nucl Med 2008; 49:1944-1951.
14. Rajendran JG, Krohn KA. Imaging hypoxia and angiogenesis in tumors. Radiol Clin North Am 2005; 43:169-187. (Pubitemid 40326567)
15. Van Loon J, Janssen MH, Ollers M, Aerts HJ, Dubois L, Hochstenbag M, et al. PET imaging of hypoxia using [18F]HX4: a phase I trial. Eur J Nucl Med Mol Imaging 2010; 37:1663-1668.
16. Adamsen TCH, Grierson JR, Krohn KA. A new synthesis of the labeling precursor for [18F]-fluoromisonidazole. J Label Compd Radiopharm 2005; 48:923-927. (Pubitemid 41659195)
17. Fuchtner F, Steinbach J, Mading P, Johannsen B. Basic hydrolysis of 2-[18F] fluoro-2,3,4,6-tetra-O-acety-l-D-acetyl-glucose in the preparation of 2-[18F]fluoro-deoxy-D-glucose. Appl Radiat Isot 1996; 47:61-66.
18. Ruan K, Song G, Ouyang G. Role of hypoxia in the hallmarks of human cancer. J Cell Biochem 2009; 107:1053-1062.
19. Koh WJ, Rasey JS, Evans ML, Grierson JG, Lewellen TK, Graham MM, et al. Imaging of hypoxia in human tumors with [F-18] fluoromisonidazole. Int J Radiat Oncol Biol Phys 1992; 22:199-212.
20. Nunn A, Linder K, Strauss HW. Nitroimidazoles and imaging hypoxia. Eur J Nucl Med 1995; 22:265-280.
21. Krohn KA, Link JM, Mason RP. Molecular imaging of hypoxia. J Nucl Med 2008; 49 (Suppl 2):129S-148S. (Pubitemid 351948041)
22. Piert M, Machulla HJ, Picchio M, Reischl G, Ziegler S, Kumar P, et al. Hypoxia-specific tumor imaging with 18F-fluoroazomycinarabinoside. J Nucl Med 2005; 46:106-113.
23. Dubois L J, Lieuwes NG, Janssen MH, Peeters WJM, Windhorst AD, Walsh JC, et al. Preclinical evaluation and validaion of [18F]HX4, a promising hypoxia marker for PET imaging. Proc Natl Acad Sci USA 2011; 108: 14620-14625.